Hyaluronic Acid-modified Redox-sensitive Hybrid Nanocomplex Loading With siRNA for Non-small-cell Lung Carcinoma Therapy

Daoyuan Chen, Peng Zhang, Minghui Li, Congcong Li, Xiaoyan Lu, Yiying Sun, Kaoxiang Sun

Abstract

A novel hyaluronic acid (HA)-modified hybrid nanocomplex, HA-SeSe-COOH/siR-93C@PAMAM, was developed to efficiently deliver siRNA into tumor cells via redox-mediated intracellular disassembly. By utilizing a diselenide bond (-SeSe-) linkage, the system achieves dual responsiveness to glutathione (GSH) and reactive oxygen species (ROS). In vitro studies in A549 cells demonstrated low cytotoxicity and significant transfection efficiency, while in vivo studies showed a 74% inhibition of tumor growth and prolonged blood circulation. This study highlights the potential of diselenide-modified HA for enhancing the stability, safety, and therapeutic efficacy of siRNA delivery in oncology.

Introduction

Non-small-cell lung carcinoma (NSCLC) frequently involves mutations in the KRAS gene, making RNA interference (RNAi) an attractive therapeutic strategy. However, the clinical application of small interfering RNA (siRNA) is hindered by its rapid enzymatic degradation in systemic circulation and its inability to cross cell membranes due to its negative charge. Poly(amidoamine) (PAMAM) dendrimers have emerged as effective delivery vehicles due to their ability to package siRNA and facilitate endosomal escape via the "proton sponge" effect. Nevertheless, the high surface positive charge of bare PAMAM leads to systemic toxicity and rapid clearance. To address these issues, researchers have developed a "cloaked" delivery system that remains stable during transport but triggers cargo release specifically within the tumor microenvironment.

Design and Synthesis of the Nanocomplex

The researchers engineered a multi-layered hybrid nanocomplex consisting of a positively charged core and a responsive shell. The core was formed by complexing KRAS-targeting siRNA (siR-93C) with G4 PAMAM dendrimers. This core was then coated with a novel derivative of Hyaluronic Acid (HA) modified with diselenide bonds (-SeSe-). Unlike traditional disulfide bonds, diselenide linkages are sensitive to both high levels of glutathione (GSH) and reactive oxygen species (ROS), both of which are characteristic of the tumor microenvironment. This dual-responsive mechanism ensures precise intracellular release of the siRNA cargo.

Physicochemical Characterization

The optimization of the nanocomplex involved varying the ratio of the HA-SeSe-COOH shell to the siR-93C@PAMAM core. The resulting particles were evaluated for size and polydispersity index (PDI) to determine the most stable configuration for delivery.

Table 1: Particle size and PDI of HA-SeSe-COOH/siR-93C@PAMAM at various mass ratios.

As shown in the characterization data, the optimized nanocomplex achieved a uniform size of approximately 181 nm with a narrow PDI (0.19) at a mass ratio of 3.0/1. The negative surface charge (-24.6 mV) provided by the HA shell is critical for avoiding immune clearance and reducing the inherent toxicity of the PAMAM core.

In Vitro and In Vivo Efficacy

The HA shell serves a dual purpose: it acts as a protective shield and an active targeting ligand for CD44 receptors, which are overexpressed in lung cancer cells. In A549 cell lines, the nanocomplex demonstrated rapid lysosomal escape and significant knockdown of KRAS protein expression.

In vivo studies using BALB/c nude mice xenograft models further validated the system's efficacy. The HA-SeSe-COOH/siR-93C@PAMAM treatment resulted in a 74% inhibition of tumor volume compared to saline controls. Furthermore, histological analysis (H&E staining) confirmed that the HA-shielded version eliminated the lung and kidney damage typically associated with bare PAMAM complexes, demonstrating a superior safety profile.

Conclusion

The development of the HA-SeSe-COOH/siR-93C@PAMAM nanocomplex represents a significant advancement in redox-sensitive delivery systems. By integrating diselenide-mediated dual responsiveness with HA-based active targeting, the platform achieves high stability in circulation and efficient gene silencing within the tumor. Future research may explore the long-term metabolic fate of selenium and the potential for co-delivering siRNA with traditional chemotherapeutic agents to further enhance therapeutic outcomes in NSCLC.

Summary updated

Abstract

Abstract A novel hyaluronic acid (HA)-modified hybrid nanocomplex HA-SeSe-COOH/siR-93C@PAMAM which could efficiently deliver siRNA into tumor cells via a redox-mediated intracellular disassembly, was constructed for enhance antitumor efficacy. Thereinto, siR-93 (siRNA) and positive PAMAM were firstly mixed into the electrostatic nano-intermediate, and then diselenide bond (-SeSe-)-modified HA was coved to shield excessive positive charges. This hybrid nanocomplex displayed uniform dynamic sizes, high stability, and controlled zeta potentials and narrow PDI distribution. Moreover, the -SeSe- linkage displayed GSH/ROS dual responsive properties, improving intracellular trafficking of siRNA. In vitro assays in A549 cell line presented that HA-SeSe-COOH/siR-93C@PAMAM has low cytotoxicity, rapid lysosomal escape and significant transfection efficiency; besides, an efficient proliferation inhibition ability and enhanced apoptosis. Furthermore, in animal studies, this negative-surfaced hybrid nanocomplex showed a prolonged circulation in blood and improved inhibition of tumor growth. All these results verified our hypothesis in this study that diselenide bonds-modified HA could promote not only stability and safety of nanoparticles in vivo but also intracellular behavior of siRNA via redox-dual sensitive properties; furthermore, this hybrid nanocomplex provided a visible potential approach for siRNA delivery in antitumor field.
BibTeX
@inproceedings{chen2022hyaluronic,
  author = {Daoyuan Chen and Peng Zhang and Minghui Li and Congcong Li and Xiaoyan Lu and Yiying Sun and Kaoxiang Sun},
  title = {{Hyaluronic Acid-modified Redox-sensitive Hybrid Nanocomplex Loading With siRNA for Non-small-cell Lung Carcinoma Therapy}},
  booktitle = {Drug},
  year = {2022},
  doi = {10.1080/10717544.2022.2032874},
}
Figure